Volume 186 - Issue 9
Accidental death from acute selenium poisoning
Author: Peter S Lavercombe
Med J Aust 2007; 186 (9): 487-488. || doi: 10.5694/j.1326-5377.2007.tb01018.x
Published online: 7 May 2007
Published online: 7 May 2007
In reply: The myth we referred to is the commonly held misperception by a significant percentage of the population that natural therapies are inherently safe. As Lewis and Brighthope very correctly point out, the dose ingested by our patient was hugely in excess of any recommended maximum. We believe this is evidence of the misperception, as most patients would not dream of taking 10 or 20 thousand times the maximum dose of “non-natural” remedies, because they recognise that all such remedies have side effects. Our patient’s confidence that he could safely take such a huge dose was, we consider, at least partly a consequence of his belief in the myth that natural therapies are safe.
The fact that the dosage of selenium in nutritional supplements is strictly regulated does not prevent problems such as this — where patients obtain information of variable quality on the Internet, make their own arrangements to obtain the product, and then ingest a toxic amount.
Our article was in no way part of “an underlying agenda to discredit natural products”; it merely highlighted the risks inherent in self-medication based on information of variable quality obtained from the Internet, coupled with the impression that natural therapies are inherently safe. We hope that our call for adverse outcomes of complementary and alternative medicines to be better publicised will go some way to preventing such a tragic error occurring again.
When ‘Liver Enzymes’ Are Not Hepatic: Late-Onset Pompe Disease
Shauna Madigan, Georgina England, Wayne Rankin
Fatty Liver Disease in Australia: A Narrative Review on the Epidemiology, Natural History, Prognostication and Management in People With Metabolic Dysfunction
Karl Vaz, Daniel Clayton-Chubb, William W. Kemp, Stuart K. Roberts, Ammar Majeed
The early implementation phase of the Omega‐3 Test‐and‐Treat Program for reducing the risk of preterm birth, South Australia, 2021–22: an implementation evaluation study
Karen P Best, Celine Northcott, Lucy A Simmonds, Philippa Middleton, Lisa N Yelland, Vanessa Moffa, Khoa Lam, Penelope Coates, Cornelia Späth, Carol WK Siu, Karen Glover, Rhiannon Smith, Robert Gibson, Maria Makrides
Cause‐specific mortality among Queensland people with cirrhosis, by cirrhosis aetiology and decompensation status, 2007–22: a retrospective cohort study
Vikas Bhasker, Jessica R Fong, Paul J Clark, Gunter F Hartel, Richard Skoien, James O’Beirne, Elizabeth E Powell, Patricia C Valery
The role of GLP‐1 receptor agonists in the management of obesity: risks and opportunities for the Australian health care system
Patrick GM Bolton
The role of GLP‐1 receptor agonists in the management of obesity: risks and opportunities for the Australian health care system
Deshan Sebaratnam, Jessie T Lu, Helen Y Sun